Girth Control Pills
Girth control pills are dietary supplements marketed to men with the promise of increasing penile circumference, and often length, without surgery or prescription medication[^c1]. They belong to the broader male-enhancement supplement market but are distinguished by a dimensional claim: not merely firmer erections or greater stamina, but a measurable and often permanent change in anatomy. Products are sold through direct-response websites, affiliate networks, sex shops and online marketplaces in North America, Europe, Latin America, Southeast Asia and the Middle East. The category spans capsules and tablets as well as lozenges, creams, honey sachets, chocolates, coffees and, in some markets, traditional powdered medicines.
The size promises are concrete. Vimax states that the average user can expect 3–4 inches of lengthening and a 25 percent increase in girth[^c2]. Vietnamese advertising offers an increase of three to six centimeters retained after a four-to-six-week course[^c18], and Brazil's XTRASIZE promised up to 7.5 centimeters in both length and thickness[^c17]. These claims are typically supported by testimonials, before-and-after images and references to circulation, testosterone or tissue growth, rather than by controlled trials. The proposed mechanisms are biologically selective: erection genuinely depends on blood flow, but no described pathway converts transient vasodilation into new penile tissue.
The clinical evidence does not support the products. No whole-product randomized trial with a circumference endpoint has been published, and the only measured gains from any intervention come from traction devices (under two centimeters of flaccid length) and injectable fillers. Most men who seek such products already have normal anatomy, and because the products are classified as dietary supplements they reach the market without pre-market efficacy review. The full evidence, including the 2026 meta-analysis and the 2025 review figures, is set out in [[overview/girth-control-pills]].
The gap between regulation and evidence has produced a persistent enforcement problem. Testing has found hidden prescription drugs in a large share of products bought on major marketplaces: all 29 male-enhancement or weight-loss products purchased on Amazon in one FDA exercise contained undeclared active ingredients[^c4]. In 2026 the pattern widened. The FDA found sildenafil and acetaminophen in 10 Day Forecast[^c12]; Indonesia's BPOM identified the previously unseen PDE5 inhibitor pyrimidenafil in three male-stamina products[^c13]; Spain withdrew four honey products containing sildenafil[^c14]; Czech inspectors found therapeutic-dose sildenafil in two supplements[^c15]; and Australia's TGA reported eleven products containing undeclared sildenafil, tadalafil or dapoxetine[^c16]. Earlier recalls had already documented testosterone propionate and flibanserin in male-oriented capsules[^c8][^c9], and chocolate and liquid sachets carrying hidden PDE5 inhibitors[^c10][^c11]. The category's history is intertwined with fraud enforcement, from Enzyte's conviction over "made-up claims about size increases, fake customer satisfaction ratings, and fictitious doctors"[^c5] to modern subscription schemes and AI-manipulated physician endorsements.